ClariPi Inc.

| Category | Enterprise Creation |
|--|---|
| O Corporation (Preliminary | ClariPi Inc. |
| Enterprise) | Cialiff Inc. |
| ○ Representative | Kim Jonghyo, Park Hyunsook |
| ○ Establishment year | 6 February, 2015 |
| O Specialized Field | Artificial Intelligence Medical Imaging Solution |
| ○ Address | 3F, 70-15, Ihwajang-gil, Jongno-gu, Seoul, 03088, Republic of KOREA |
| ○ Home page | 1. Homepage: http://www.claripi.com/ |
| ○ Enterprise Brief Introduction | ClariPI provides innovative solutions to complex problems in the field of medical imaging by integrating big data with artificial intelligence image processing technologies. Our solutions provide imaging experts with clearer information and easy-to-use decision guidance for making confident diagnosis. |
| • Product and Pipeline Introduction | ClariCT.AI is the company's artificial intelligence deep-learned technology that uses noise reduction technology. It is both FDA cleared and CE marked to offer a significant increase in CT image clarity, even with ultra-low-dose. It uses a deep convolutional neural network, trained to work in a vendor-agnostic way, to reduce noise and enhance image clarity for low-dose and ultra-low-dose DICOM CT images. Trained with over one million patient images containing varying degrees of noise for different body parts, its Clarity Engine separates image noise selectively while enhancing underlying structures; thus, providing clarity restored images. ClariPulmo is an AI-powered tri-functional solution kit best suited for low-dose lung CT screening. Our powerful pre-trained deep learning model provides accurate quantitative analysis of lung nodules as well as low-attenuation and high-attenuation lesions such as emphysema and pneumonia from low-dose CT images, despite strong image noise and varying scan conditions. The ClariPulmo in conjunction with the ClariCT.AI can help achieve the best practice in lung screening by reducing noise induced bias with this 3D reporting. ClariSigmam is an innovative breast cancer prediction marker. It is a breast density assessment solution that provides accurate and consistent density estimates from standard digital mammograms. Quantitative breast density is the main indicator in breast cancer screening and diagnosis. The powerful pre-trained deep learning model ensures to make consistent clinical decision marking in an objective and convenient way. Novel Deep Learning Technology provides a fully automated quantification for breast and mammary area and proportion density measurements. With the world's highest accuracy rate ClariAdipo is a system that helps to predict the risk of developing metabolic syndrome. It is a standalone S/W that analyzes DICOM CT abdomen fat image data sets. |
| Patent and Certification, Licensing, Thesis, Investment status, etc. | Patent : 6 including APPARATUS AND METHOD FOR CT IMAGE DENOISING BASED ON DEEP (US10891762) Certification : GMP, ISO 13485 License : FDA, CE, MFDS Thesis : 8 (Korea 2, Europe 6) Noise reduction approach in pediatric abdominal CT combining deep learning and dual-energy technique Incremental Image Noise Reduction in Coronary CT Angiography Using a Deep Learning-Based Technique with Iterative Reconstruction Application of Vendor-Neutral Iterative Reconstruction Technique to Rediatric Abdominal Computed Tomography Effect of a novel denoising technique on image quality and diagnostic accuracy in low-dose CT in patients with suspected appendictis Impact of image denoising on image quality, quantitative parameters and sensitivity of ultra-low-dose volume perfusion CT imaging |